Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.44 |
| ▸ | SLC6A9 | P48067 | 4/20 | 0.43 |
| ▸ | RORC | P51449 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | GPR6 | P46095 | 6/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24371188 | 0.86 | HCRTR1 (0.44) | CNR2SLC6A9GPR6 | |
| SCHEMBL24371182 | 0.82 | GPR6 (0.43) | CNR2SLC6A9ARGPR6PTGDR2 | |
| SCHEMBL26388243 | 0.82 | GSK3B (0.45) | CNR2SLC6A9ARGPR6PTGDR2 | |
| SCHEMBL5043693 | 0.81 | PTGDR2 (0.48) | CNR2SLC6A9PTGDR2 | |
| SCHEMBL943645 | 0.81 | CNR2 (0.48) | CNR2SLC6A9PTGDR2 | |
| SCHEMBL943472 | 0.81 | CNR2 (0.48) | CNR2SLC6A9GPR6 | |
| Hydrochloric Acid SCHEMBL30468092 | 0.81 | CNR2 (0.41) | CNR2SLC6A9ARGPR6PTGDR2 | |
| SCHEMBL20855586 | 0.80 | AR (0.50) | SLC6A9AR | |
| SCHEMBL30468153 | 0.80 | AR (0.50) | SLC6A9AR | |
| SCHEMBL23287020 | 0.78 | MAP3K5 (0.42) | SLC6A9GPR6PTGDR2GPR119MAP3K5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303547-A1 | N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2023-09-28 | — | — | US | disclosed |
| US-20230303547-A1 | N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2023-09-28 | — | — | US | disclosed |
| US-20230303547-A1 | N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2023-09-28 | — | — | US | disclosed |
| EP-4161920-A1 | N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | Mission Therapeutics Limited (GB) | 2023-04-12 | — | — | EP | disclosed |
| CN-115698001-A | N-cyanopyrrolidines having activity as USP30 inhibitors | 特殊治疗有限公司 | 2023-02-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303547-A1 | N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | USP30, USP1, USP47 | CNR2 3351/4885SLC6A9 4764/4885RORC 3615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.